The majority of patients with late stage castration-resistant prostate cancer (CRPC) develop
bone metastases that often result in significant bone pain. Therapeutic palliation strategies …

Theranostics is a precision medicine which integrates diagnostic nuclear medicine and
radionuclide therapy for various cancers throughout body using suitable tracers and …

Objectives: There are limited studies characterizing cancer-related symptoms in outpatient
advanced prostate cancer patients. The aim of this retrospective study was to describe the …

In this review, we examine the chelating ligand design and coordination complexes of
radioactive lanthanide isotopes. Where appropriate, discussion is placed in the context of …

Background Patients with polymetastatic cancer are most often treated with systemic therapy
to improve overall survival and/or delay progression, with palliative radiotherapy reserved …

Recent advances have improved the effectiveness, decreased the complications, and
expanded the implications of radiation therapy. These advances include three-dimensional …

Results Complete pain relief was found in 40% of women and 40% of men treated using 153
Sm-EDTMP and in 25% of women and 33% of men treated with 89 Sr. No analgesic effect …

Objectives Castration-resistant prostate cancer (CRPC) has retained a guarded prognosis,
with historical survival estimates of 18 to 24 months. However, the landscape of available …

INTRODUCTION: Radionuclide therapy (RNT) is an effective method for bone pain palliation
in patients suffering from bone metastasis. Due to the long half-life, easy production and …

It has been 25 years since the oligometastatic hypothesis was formally defined and nearly a
century since the first published report of an oligometastatic patient being treated with …